A sizable group were reluctant to give up a painkiller proven to have fewer gastrointestinal side effects than others and were not convinced the available alternatives were any safer, participants said . (On Friday, Pfizer Inc. issued a warning that its Cox-2 drug Bextra may increase cardiovascular risk for some patients .) Duke University cardiologist Robert Califf argued strenuously on one teleconference for keeping the drug on the market with a much stronger warning label . He had been railing publicly for some time about the absence of long-term cardiovascular risk studies on painkillers, a